CN1879658A - Application of cantharis in medicament preparation - Google Patents
Application of cantharis in medicament preparation Download PDFInfo
- Publication number
- CN1879658A CN1879658A CNA2006100262777A CN200610026277A CN1879658A CN 1879658 A CN1879658 A CN 1879658A CN A2006100262777 A CNA2006100262777 A CN A2006100262777A CN 200610026277 A CN200610026277 A CN 200610026277A CN 1879658 A CN1879658 A CN 1879658A
- Authority
- CN
- China
- Prior art keywords
- mylabris
- tumor
- cell
- mice
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims description 28
- 238000002360 preparation method Methods 0.000 title claims description 16
- 241000131283 Cantharis Species 0.000 title abstract 7
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 241000124079 Mylabris Species 0.000 claims description 71
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 12
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 206010047642 Vitiligo Diseases 0.000 claims description 4
- -1 N-hydroxycantharidin Chemical compound 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 claims description 2
- 229940095758 cantharidin Drugs 0.000 claims description 2
- 229930008397 cantharidin Natural products 0.000 claims description 2
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 claims description 2
- JAABVEXCGCXWRR-FBXFSONDSA-N rel-norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 76
- 201000011510 cancer Diseases 0.000 abstract description 8
- 230000036039 immunity Effects 0.000 abstract description 5
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000036737 immune function Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 210000000822 natural killer cell Anatomy 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 102000004388 Interleukin-4 Human genes 0.000 description 12
- 108090000978 Interleukin-4 Proteins 0.000 description 12
- 102100037850 Interferon gamma Human genes 0.000 description 10
- 108010074328 Interferon-gamma Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000022534 cell killing Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000028327 secretion Effects 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000000118 anti-neoplastic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 5
- 239000003470 adrenal cortex hormone Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 210000000447 Th1 cell Anatomy 0.000 description 4
- 210000004241 Th2 cell Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 240000002853 Nelumbo nucifera Species 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010040825 Skin depigmentation Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000010165 autogamy Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000834 fixative Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000003526 lymphopoietic effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011022 operating instruction Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013605 boiled eggs Nutrition 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application of cantharis and cantharis mixture, wherein said application comprises: (1) the invention develops new application of cantharis and cantharis mixture; (2) the inventive cantharis and cantharis mixture have low toxicity and strong pharmacological function, and wider application; (3) the invention can restrain cancer growing and adjust the immunity of human body, to support clinical cancer treatment.
Description
Technical field
The present invention relates to the purposes of Mylabris, mylabris mixture, relate in particular to their application in pharmaceutical field.
Background technology
Mylabris is just on the books in " Renzhai Zhi Zhi Fang, Effective Recipes from Renzhai House " in 13rd century, available controlling in breast carcinoma and abdominal part cancer.Ancients''s " the Mylabris boiled egg is abandoned Mylabris food egg " also commonly used folk prescription treatment hepatocarcinoma and other cancer in digestive system are still continued to use among the people so far.Chinese medicine is thought Mylabris acrid in the mouth cold in nature, and is poisonous.According to the Shennong's Herbal record, Mylabris can be treated diseases such as carbuncle, ulcer, tinea skin ulcer, has the effect of counteracting toxic substances erosion cellulitis, removing blood stasis eliminating stagnation.It also has multiple new purposes clinical discovery, treats some difficult miscellaneous diseases and has unique curative effect, as treatment rheumatalgia, neuralgia, globus hystericus, alopecia areata, cyclomastopathy, rhinitis, infection wart, hepatitis, cancerous protuberance etc.
Primary hepatocarcinoma (PHC is hereinafter to be referred as hepatocarcinoma) is a common malignant neoplasm in digestive tract, and the East Asia Region is hepatocarcinoma district occurred frequently, the world, and its sickness rate occupies the 3rd in malignant tumor, and male's onset of liver cancer rate is 3 times of women approximately, and 73% is the male among the new case.Hepatocarcinoma case fatality rate height (mortality rate/sickness rate=0.95), death 39.6 ten thousand in 2000, arranged second in the malignant tumor cause of the death.How preventing and treating primary disease effectively is the important topic that the world of medicine faces, and wide prospect has been opened up in immunology and the molecular biological basic research that constantly develops into the oncology.The traditional Chinese medical science thinks that the evil poison of impression is the main diseases therefore of hepatocarcinoma, and dispeling evil poison is the important method of treatment hepatocarcinoma.Modern study confirms that again immune system can influence tumor growth, and the host of lotus tumor often has the change of immunologic hypofunction.Therefore, strengthen and adjustment tumor patient immunologic function, will help control tumor.At present, Chinese medicine has all been obtained gratifying progress at aspects such as suppressing tumor growth, transfer, raising patient life quality and prolongation patient life.Mid and late liver cancer the patient immune function often be badly damaged, and especially based on cellular immune function decreased, the raising cellular immune function has positive role for the alleviation of the liver cancer patient state of an illness.
Systemic lupus erythematosus (sle) is a kind of more common autoimmune disease that involves the many organs of multisystem, because cell and humoral immune function obstacle produce multiple autoantibody.Pathogeny mainly is because immune complex forms.The state of an illness is outbreak repeatedly and alleviates alternation procedure.
Vitiligo is a kind of common depigmentation skin mucosa disease, is mainly caused skin melanocyte disappearance or melanocyte dyspoiesis and is caused that sickness rate is about 0.1-2% in China by factors such as neuropsychiatric abnormalities or immune dysfunctions.Except that the white macula that the local skin depigmentation forms, the patient does not have other any subjective symptoms usually, but owing to be more common in youngster, and it is attractive in appearance to influence appearance, often causes a kind of invisible mental pressure to the patient, so influence normal live and work.
At present to H
22Hepatocarcinoma, systemic lupus erythematosus (sle), vitiligo also do not have effective medicine.
Summary of the invention
The objective of the invention is to following several respects:
The application of Mylabris in the medicine of the disease that preparation treatment or epidemic prevention imbalance cause.
Mylabris is at preparation treatment or prevention H
22Application in the medicine of hepatocarcinoma.
The application of Mylabris in the medicine of preparation treatment or prevention system lupus erythematosus.
Mylabris is in preparation treatment or prevent application in the leukodermic medicine.
The application of mylabris mixture in the medicine of the disease that preparation treatment or epidemic prevention imbalance cause.
Mylabris mixture is at preparation treatment or prevention H
22Application in the medicine of hepatocarcinoma.
The application of mylabris mixture in the medicine of preparation treatment or prevention system lupus erythematosus.
Mylabris mixture is in preparation treatment or prevent application in the leukodermic medicine.
Wherein said mylabris mixture be selected from cantharidin, N-hydroxycantharidin, disodium cantharidinate, norcantharidin one or more.
The objective of the invention is to realize by following technical method:
The present invention is with hepatocarcinoma (H
22) mice is model, carries out Mylabris, mylabris mixture heavily reaches tumour inhibiting rate, T lymphopoiesis function, NK killing ability, T lymphocyte phenotype, cytokine experiment to mice body weight, the tumor of tumor-bearing mice.The result has shown that Mylabris, mylabris mixture have the effect that suppresses tumor tissue growth, and the immunologic function of tumor-bearing mice is had certain regulating action.
The application of the disclosed Mylabris of the present invention in pharmacy, its advantage shows:
(1) the present invention has excavated new medical application to Mylabris, mylabris mixture, has opened up a new application.
(2) Mylabris of the present invention, mylabris mixture safety and low toxicity, pharmacological action is strong, is indicating well prospect in medicine.
(3) Mylabris, mylabris mixture have the double effect that suppresses tumor growth and regulate body's immunity, for clinical treatment tumour provides foundation.We think that mylabris mixture antineoplastic action mechanism is by improving CD4 in the tumor-bearing mice splenocyte
+, CD8
+T lymphocyte function and change CD4
+/ CD8
+Ratio strengthens NK cell killing function, induces IFN-γ and IL-4 secretion, and cell and the humoral immunization of improving tumor-bearing mice realize.
Description of drawings
Fig. 1 shows that Mylabris is to tumor-bearing mice body weight and the heavy influence of tumor
Fig. 2 shows that Mylabris is to the lymphopoietic influence of tumor-bearing mice T
Annotating 1. normal group T lymphocyte transformation stimulation index is 42.01;
Notes 2. compare * P＜0.01 with the normal saline group.
Fig. 3 shows the influence of Mylabris to tumor-bearing mice NK cell killing function
Annotate: compare * P＜0.01 with the normal saline group.
Fig. 4 shows the influence that Mylabris changes tumor-bearing mice T cell subsets.
Fig. 5 shows the influence of Mylabris to tumor-bearing mice secretion of gamma-IFN ability
Annotate: compare * P＜0.01 with the normal saline group.
Fig. 6 shows the influence of Mylabris to tumor-bearing mice secretion IL-4 ability
Annotate: compare * P＜0.01 with the normal saline group.
The specific embodiment
Below in conjunction with embodiment the present invention is further described.
Embodiment 1
Mylabris is at preparation treatment or prevention H
22Application in the medicine of hepatocarcinoma
1 material and method
1.1 experiment material
1.1.1 the preparation of Mylabris: get Chinese medicine Mylabris decoction pieces and put in the decoction container, add and be equivalent to medical material amount 5-7 cold water soak 1-2h doubly, boil 30min, filter.Medicinal residues add 3-5 times of water gaging to be continued to decoct, and boils 20min, filters.Merge filtrate twice, be condensed into the medicinal liquid that is equivalent to primary crude drug 0.01g/ml in water-bath, cool off the sterilization medicine bottle of packing into, it is standby to put 4 ℃ of refrigerators.
1.1.2 animal: the C57BL/6 mice, male, 10 ages in week are available from Shanghai Chinese Academy of Sciences animal center.
1.1.3 tumor strain: hepatocarcinoma H
22The tumor strain is provided by Shanghai Institute of Immunology.
1.1.4 reagent: ConA (Sigma company), CD3, CD4, CD8 monoclonal antibody (eBioScience company), NK cell killing reagent (autogamy of Shanghai City immune Research institute),
3H-TdR (Institute for Atomic Research, Shanghai), IFN-γ and IL-4 detection kit (brilliant U.S. company).
1.2 experimental technique
1.2.1 modeling method: get the H that growth 7-9d goes down to posterity and inoculates under the aseptic condition
22Cell strain is with cell 5 * 10
6It is subcutaneous to be inoculated in every right side of mice axillary fossa.
1.2.3 animal grouping and medication: 30 of mices, 10 as normal group, and all the other are all by last method modeling.After the mouse inoculation tumor 5 days, be divided into normal saline group and experimental group at random, 10 every group, the normal saline group gives normal saline and handles, and experimental group gives Mylabris decocting liquid 0.01g/ml, only all irritates stomach 0.2ml/, successive administration 15 days.
1.2.4 collection of specimens: drug withdrawal next day, disconnected neck is put to death mice, peels off tumor tissues and the aseptic spleen of getting.
1.3 detection index
1.3.1 mice body weight, tumor heavily reach tumour inhibiting rate: after stomach is raised 15 days, take by weighing two groups of mice body weight; The complete tumor of peeling off behind the execution mice takes by weighing tumor with electronic balance and weighs, and calculates tumour inhibiting rate.
1.3.2T lymphopoiesis function: adopt
3H-TdR mixes method.In the flat culture plate in 96 holes, every hole adds mouse boosting cell suspension 100 μ l, and concentration is 5 * 10
6/ ml, cultivate in three multiple holes.Simultaneously, add ConA 10 μ l respectively.In 37 ℃, 5%CO
2Cultivate 72h under the condition.16h before stopping cultivating, every hole adds
3H-TdR 1 μ Ci.With the cell harvesting instrument with cell harvesting on glass fiber filter paper, β-liquid scintillation instrument measures cpm value, and the calculating stimulation index.
1.3.3NK killing ability: K562 cell (target cell) concentration of adjusting mouse boosting cell (effector lymphocyte) and In vitro culture with RPMI-1640 respectively is 5 * 10
6/ ml and 1 * 10
5/ ml.In imitating: target=50: 1 ratios, respectively get 100 μ l and add the flat culture plate in 96 holes, 37 ℃, 5%CO
2Co-cultivation 4h under the condition.And establish that nature discharges and maximum release group contrasts as the experiment yin and yang attribute.1000rpm then, centrifugal 5min.Draw supernatant 100 μ l, add substrate solution 100 μ l, leave standstill the 3min colour developing.Add 1N HCL cessation reaction again, the 490nm wavelength reads the OD value.Calculate the percentage rate that kills and wounds of NK cell.
1.3.4T lymphocyte phenotype: adopt direct immunofluorescence and flow cytometry analysis.Get mouse boosting cell 1 * 10
6, adding an amount of PE-Cy5-CD3, FITC-CD4 and PE-CD8 mixing monoclonal antibody, the room temperature lucifuge is hatched 20min.1000rpm, centrifugal 5min, wash 2 times after, add 300 μ l fixatives, last machine testing.
1.3.5 cytokine: adopt the ELISA method.Collect the culture supernatant of mouse boosting cell after ConA stimulates 24h, measure the content of IFN-γ and IL-4 according to cytokines measurement test kit operating instruction respectively.1.4 statistical procedures: adopt the Statpal T of group inspection statistics to analyze the significance of difference of each group data.
2 results
2.1 Mylabris heavily reaches the influence of tumour inhibiting rate to tumor-bearing mice body weight, tumor: the result as shown in Figure 1.Compare with normal group, two groups of tumorigenic mice body weight all alleviate, and experimental mice weight loss obvious (P=0.001), but the experimental mice tumor weight significantly weighs (P=0.0015), inhibitory rate 65.76% less than normal saline group mouse tumor.Show that Mylabris can effectively suppress the growth of rat liver cancer cell.
2.2 Mylabris is to the lymphopoietic influence of tumor-bearing mice T: two groups of T lymphocyte transformation functions all have remarkable reduction than normal mice.Significantly (SI=4.34＞3 P=0.00129), have stronger multiplication capacity to the increase of experimental mice T lymphocyte transformation stimulation index, the results are shown in Figure 2.Illustrate that Mylabris can significantly raise the T lymphopoiesis function of mice.
2.3 Mylabris is to the influence of tumor-bearing mice NK cell killing function: with normal group relatively, simple stomach is raised normal saline group NK cell killing activity there was no significant difference, illustrate suffer from hepatocarcinoma after, can not stimulate NK cells in mice to produce immunne response effectively at tumor.Experimental mice NK cell killing activity significantly increases, and 5 times (P＜0.005) for the normal saline group the results are shown in Figure 3.Illustrate that Mylabris can strengthen the killing ability of suffering from the tumor NK cells in mice.
2.4 the influence that Mylabris changes tumor-bearing mice T cell subsets: as shown in Figure 4, compare with normal group, two mice with tumor group T cell quantities all have obvious decline (P＜0.05), and its immunologic hypofunction is described.Simultaneously, two groups of mice periphery T cell subgroup ratio generation significant change: CD4
+/ CD8
+Ratio is inverted, and this may be because after tumor takes place, mouse interior tumor specific C D8
+The result of T cell clone propagation.And the normal saline group is compared with experimental group, and the latter more can change t lymphocyte subset group ratio.
2.5 Mylabris is to the influence of tumor-bearing mice secrete cytokines ability: IFN-γ measures and shows and sees Fig. 5, and experimental mice T emiocytosis IFN-γ ability has remarkable rising (P＜0.05), illustrates that Mylabris can significantly raise CD4
+The secretion capacity of Th1 cell, and and then raise the mouse cell immunologic function, promote CD8
+The antitumor action of cytotoxic T cell.The IL-4 testing result shows sees that Fig. 6, the ability of experimental mice T emiocytosis IL-4 have remarkable rising (P＜0.001), illustrates that Mylabris can significantly raise CD4
+The secretion capacity of Th2 cell, and and then rise mouse humoral immune function.Comprehensive above two kinds of situations, experimental group can raise the mouse cell immunologic function, and therefore humoral immune function that again can the effective stimulus mice can effectively suppress the growth of mouse tumor.
3 discuss
The traditional Chinese medical science does not have the name of disease of " hepatocarcinoma " in ancient times, but it is very abundant to be similar to the record of hepatocarcinoma, as " jaundice ", " tympanites ", " gathering ", " note of the ancient Chinese abdominal mass " etc.The traditional Chinese medical science thinks that the pathogeny of this class disease mainly is the evil poison of impression, and body is just not anti-evil, causes imbalance of YIN and YANG, the function obstacle, meridians block, and QI-blood circulation is not normal, qi depression to blood stasis, wet poly-expectorant coagulates, and strongly fragrant fire-transformation of a specified duration causes gas, blood, wet, heat, expectorant, the stasis of blood, the mutual knot of poison forms hepatocarcinoma eventually.Modern medicine thinks that the generation development of body's immunological function and tumor has substantial connection.Low or when being suppressed, the tumor incidence rate increases when host immune function, and immunological function of cancer patients is suppressed the two reciprocal causation when the growth of carrying out property of tumor.Enhancing human body immunity function how is brought into play the antineoplastic immune mechanism of body better, always is the important topic of tumor immunology research.We have tentatively inquired into Mylabris to the immune influence of tumor-bearing mice at the pathogenic characteristic of hepatocarcinoma " expectorant ", " stasis of blood ", " poison " in conjunction with tumor immunology.
This experiment shows that Mylabris can obvious suppression tumor-bearing mice growth of tumor, inhibitory rate 65.76%, and P=0.0015, and the mice body weight is reduced, and depilation phenomenon takes place, its effectively kill tumor cell is described, have certain toxic and side effects.
The antineoplastic immune of body mainly relies on the cellular immunization of T cell mediated.Mature T lymphocyte is divided into CD4
+And CD8
+Two subgroups of T lymphocyte.It is generally acknowledged: CD4
+The T lymphocyte produces a large amount of cytokines, CD8
+The T lymphocyte is at CD4
+Can killing tumor cell under the lymphocytic auxiliary and effect of cytokines, first anti tumor immune response mainly relies on CD8
+The participation of T lymphocyte and natural killer cell.The CD8 of tumour-specific
+The T lymphocyte also has direct lethal effect to tumor cell.Lack CD4
+And CD8
+T lymphocyte, and CD4
+/ CD8
+The reduction of ratio is to cause one of low reason of antineoplastic immune effect.Discover that lycium barbarum polysaccharide can promote CD4
+, CD8
+Lymphocytic propagation of T and activation.There are report arsenic trioxide and Radix Morindae Officinalis can make CD3
+, CD4
+Cell proportion and CD4
+/ CD8
+Ratio obviously rise.This experiment is passed through
3H-TdR mixes method and Flow cytometry finds that Mylabris can extremely obviously promote T lymphopoiesis (P=0.00129), and changes t lymphocyte subset group ratio, illustrates that it has the enhancing immunization of cell.
NKT (nature killer, NK) cell in the monitoring of body tumor, resist infection, and in immunologic function is regulated, play a significant role, it is the non-special part in the cellular immunization, it does not need just energy killing tumor cell of presensitization, its lethal effect does not have tumour-specific and MHC is restricted, so its non-specific kill capability reduces one of major reason of tumor development and transfer often.Previously discover that tumor mice NK cytoactive obviously reduces, this experiment has also obtained equifinality, i.e. lotus tumor (H
22) the NK cytoactive of model group mice significantly is lower than normal group, illustrate that tumor mice NK cytoactive is in serious low state, and the NK cytoactive of medicine group is apparently higher than model group (P＜0.005), thereby shows that Mylabris can strengthen lotus liver cancer mouse NK cytoactive, improves its immunity.
IFN-γ is one of important cytokine that participates in cellullar immunologic response, can promote that the Th0 cell differentiation is the Th1 cell, influences the Th1/Th2 ratio; The Th2 cell is the most effective auxiliary of B cell, and is the most important to humoral immunization, and IL-4 can promote that the Th0 cell differentiation is the Th2 cell, and suppresses the Th1 cell, secretes its serial factor, promotes humoral immunoresponse(HI).Body will be in good immune state, must keep the Th1/Th2 balance, in case Th1/Th2 is out of proportion, to the drift of Th2 direction, causes immunosuppressive condition, and the antineoplastic immune of body will be subjected to serious interference.This experiment detects medicine group mouse T cell secretion of gamma-IFN and IL-4 content all has remarkable rising (P＜0.05, P＜0.001) than model group, illustrates that Mylabris can significantly raise CD4
+The secretion capacity of Th1 and Th2 cell strengthens mouse cell immunity and humoral immune function simultaneously, therefore can effectively suppress the growth of mouse tumor.
In sum, this experiment confirm Mylabris have the double effect that suppresses tumor growth and regulate body's immunity, for clinical treatment tumour provides foundation.We think that Mylabris antineoplastic action mechanism may be by improving CD4 in the tumor-bearing mice splenocyte
+, CD8
+T lymphocyte function and change CD4
+/ CD8
+Ratio strengthens NK cell killing function, induces IFN-γ and IL-4 secretion, and cell and the humoral immunization of improving tumor-bearing mice realize.
Embodiment 2
The mylabris mixture that contains N-hydroxycantharidin is at preparation treatment or prevention H
22Application in the medicine of hepatocarcinoma
1 material and method
1.1 experiment material
1.1.1 mylabris mixture: Mylabris content is 0.02g/ml in the mylabris mixture.
1.1.2 animal: the C57BL/6 mice, male, 10 ages in week are available from Shanghai Chinese Academy of Sciences animal center.
1.1.3 tumor strain: hepatocarcinoma H
22The tumor strain is provided by Shanghai Institute of Immunology.
1.1.4 reagent: ConA (Sigma company), CD3, CD4, CD8 monoclonal antibody (eBioScience company), NK cell killing reagent (autogamy of Shanghai City immune Research institute),
3H-TdR (Institute for Atomic Research, Shanghai), IFN-γ and IL-4 detection kit (brilliant U.S. company).
1.2 experimental technique
1.2.1 modeling method: get the H that growth 7-9d goes down to posterity and inoculates under the aseptic condition
22Cell strain is with cell 5 * 10
6It is subcutaneous to be inoculated in every right side of mice axillary fossa.
1.2.3 animal grouping and medication: 30 of mices, 10 as normal group, and all the other are all by last method modeling.After the mouse inoculation tumor 5 days, be divided into normal saline group and experimental group at random, 10 every group, the normal saline group gives normal saline and handles, and experimental group gives mylabris mixture 0.02g/ml, only all irritates stomach 0.2ml/, successive administration 15 days.
1.2.4 collection of specimens: drug withdrawal next day, disconnected neck is put to death mice, peels off tumor tissues and the aseptic spleen of getting.
1.3 detection index
1.3.1 mice body weight, tumor heavily reach tumour inhibiting rate: after stomach is raised 15 days, take by weighing two groups of mice body weight; The complete tumor of peeling off behind the execution mice takes by weighing tumor with electronic balance and weighs, and calculates tumour inhibiting rate.
1.3.2T lymphopoiesis function: adopt
3H-TdR mixes method.In the flat culture plate in 96 holes, every hole adds mouse boosting cell suspension 100 μ l, and concentration is 5 * 10
6/ ml, cultivate in three multiple holes.Simultaneously, add ConA 10 μ l respectively.In 37 ℃, 5%CO
2Cultivate 72h under the condition.16h before stopping cultivating, every hole adds
3H-TdR 1 μ Ci.With the cell harvesting instrument with cell harvesting on glass fiber filter paper, β-liquid scintillation instrument measures cpm value, and the calculating stimulation index.
1.3.3NK killing ability: K562 cell (target cell) concentration of adjusting mouse boosting cell (effector lymphocyte) and In vitro culture with RPMI-1640 respectively is 5 * 10
6/ ml and 1 * 10
5/ ml.In imitating: target=50: 1 ratios, respectively get 100 μ l and add the flat culture plate in 96 holes, 37 ℃, 5%CO
2Co-cultivation 4h under the condition.And establish that nature discharges and maximum release group contrasts as the experiment yin and yang attribute.1000rpm then, centrifugal 5min.Draw supernatant 100 μ l, add substrate solution 100 μ l, leave standstill the 3min colour developing.Add 1N HCL cessation reaction again, the 490nm wavelength reads the OD value.Calculate the percentage rate that kills and wounds of NK cell.
1.3.4T lymphocyte phenotype: adopt direct immunofluorescence and flow cytometry analysis.Get mouse boosting cell 1 * 10
6, adding an amount of PE-Cy5-CD3, FITC-CD4 and PE-CD8 mixing monoclonal antibody, the room temperature lucifuge is hatched 20min.1000rpm, centrifugal 5min, wash 2 times after, add 300 μ l fixatives, last machine testing.
1.3.5 cytokine: adopt the ELISA method.Collect the culture supernatant of mouse boosting cell after ConA stimulates 24h, measure the content of IFN-γ and IL-4 according to cytokines measurement test kit operating instruction respectively.
1.4 statistical procedures: adopt the Statpal T of group inspection statistics to analyze the significance of difference of each group data.
2 results:
1. mylabris mixture has significant inhibitory effect to the tumor-bearing mice tumor.
2. experimental mice T lymphocyte transformation stimulation index and NK cell killing percentage number average significantly increase than normal saline group.
3. compare with the normal saline group, experimental group more can change t lymphocyte subset group ratio.
4. experimental mice T emiocytosis IFN-γ and IL-4 ability all have remarkable rising.
Embodiment 3
The application of Mylabris in the medicine of preparation treatment or prevention system lupus erythematosus
1. animal and material
Laboratory animal: 60 of systemic lupus erythematosus (sle) experimental rats, body weight 200 ± 10g, 160 days ages of Mus, per 4 one cages, 23 ± 2 ℃ of room temperatures, humidity 30-50%, the refining particles feedstuff,
2. grouping
We are divided into two groups of corticosteroid hormone treatments at random with above-mentioned 60 systemic lupus erythematosus (sle) experiment mices and organize 30 examples: this group injection corticosteroid hormone, every day, injection volume was 0.01g, successive administration 15 days.
30 examples are organized in the Mylabris treatment: this group gives Mylabris decocting liquid 0.01g/ml, only all irritates stomach 0.2ml/, successive administration 15 days.
3. observe
Mylabris treatment group: the required natural law of improvement of main clinic symptoms heating, arthralgia, skin butterfly erythema, urine protein, erythrocyte sedimentation rate was respectively 4.0,19.2,27.9 days and 22.8 days.
Corticosteroid hormone treatment group: the required natural law of improvement of main clinic symptoms heating, arthralgia, skin butterfly erythema, urine protein, erythrocyte sedimentation rate was respectively 9.0,23.8,47.9 days and 52 days.
Wherein 4 examples are dead in 1 year in the corticosteroid hormone treatment group.
4. result
Mylabris treatment group curative effect is better than corticosteroid hormone treatment group, and Mylabris can be in the application in the medicine of preparation treatment or prevention system lupus erythematosus.
Claims (9)
1, the application of Mylabris in the medicine of the disease that preparation treatment or epidemic prevention imbalance cause.
2, application according to claim 1 is characterized in that: described disease is H
22Hepatocarcinoma.
3, application according to claim 1 is characterized in that: described disease is a systemic lupus erythematosus (sle).
4, application according to claim 1 is characterized in that: described disease is a vitiligo.
5, the application of mylabris mixture in the medicine of the disease that preparation treatment or epidemic prevention imbalance cause.
6, application according to claim 1 is characterized in that: described mylabris mixture be selected from cantharidin, N-hydroxycantharidin, disodium cantharidinate, norcantharidin one or more.
7, application according to claim 6 is characterized in that: described disease is H
22Hepatocarcinoma.
8, application according to claim 6 is characterized in that: described disease is a systemic lupus erythematosus (sle).
9, application according to claim 6 is characterized in that: described disease is a vitiligo.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100262777A CN1879658A (en) | 2006-04-29 | 2006-04-29 | Application of cantharis in medicament preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2006100262777A CN1879658A (en) | 2006-04-29 | 2006-04-29 | Application of cantharis in medicament preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1879658A true CN1879658A (en) | 2006-12-20 |
Family
ID=37518159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006100262777A Pending CN1879658A (en) | 2006-04-29 | 2006-04-29 | Application of cantharis in medicament preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1879658A (en) |
-
2006
- 2006-04-29 CN CNA2006100262777A patent/CN1879658A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103750339B (en) | Saussurea involucrate culture health-care food and application thereof | |
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN102579803B (en) | Medicine for treating post-chemotherapy leucopenia and preparation method thereof | |
| CN1305513C (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN104524233B (en) | A kind of BRM for promoting hematopoiesis function to improve immunity and its preparation and application | |
| CN1186091C (en) | Chinese medicine injection and its production process | |
| CN1686506A (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN1679658A (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN1879658A (en) | Application of cantharis in medicament preparation | |
| CN1363283A (en) | Beetoxin injection and its preparing process | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis | |
| CN1537564A (en) | Traditional chinese medicine prepns. for treating broad-spectrum cancers | |
| CN1879836A (en) | A medicine for treating children's excessive blink, hyperkinetic syndrome and Tottre's syndrome and method for preparing same | |
| CN1879819A (en) | Medicinal pill, watered pill, honeyed pill for treating H22 liver cancer and method for preparing same | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN1879818A (en) | A medicine for treating H22-liver cancer and method for preparing same | |
| CN1298379C (en) | Medicine for curing malignant tumors of carcinoma of prostate, liver cancer and sarcoma | |
| CN1100550C (en) | Chinese medicine composition for curing various cancers | |
| CN1256117C (en) | A kind of medicine for treating chronic nonspecific ulcerative colitis and its preparation method | |
| CN103271992B (en) | Pharmaceutical composition for improving immunity | |
| CN100350953C (en) | Pharmaceutical composition for treating virus infectious high fever and preparation method thereof | |
| CN1513500A (en) | Liu-Wei-Bu-Xue granule for invigorating blood contg. six herbal medicines and its prepn. method | |
| CN108175779A (en) | Application of extract of radix astragali and radix Angelicae sinensis in treating lung cancer and reducing side effects of anticancer agent | |
| CN1380080A (en) | Medicine for curing fatty liver | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20061220 |